Organization of the stress system and its dysregulation in melancholic and atypical depression: High vs low CRH/NE states

Molecular Psychiatry

Volumn 7, Issue 3, 2002, Pages 254-275

  Gold, Phil W ^a   Chrousos, G P ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Atypical depression; Corticotropin releasing hormone (CRH); Melancholic depression; Norepinephrine (NE); Stress

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; NORADRENALIN;

ARTICLE; AUTONOMIC NERVOUS SYSTEM; CLINICAL FEATURE; DEPRESSION; DISEASE CLASSIFICATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LOCUS CERULEUS; MELANCHOLIA; NEUROBIOLOGY; NEUROPHARMACOLOGY; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOMENOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; STRESS;

BRAIN; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; DEPRESSIVE DISORDER; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; PITUITARY-ADRENAL SYSTEM; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS, PSYCHOLOGICAL;

EID: 0036212671     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001032     Document Type: Article

References (162)

1. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey
2. Three year outcomes for maintenance in therapies in recurrent depression
3. Clinical and biochemical manifestations of depression: Relation to the neurobiology of stress (Part 1 of 2 parts)
4. The clinical implications of corticotropin-releasing hormone
5. The endocrinology of melancholic and atypical depression: Relation to neurocircuitry and somatic consequences
6. Clinical and biochemical manifestations of depression: Relation to the neurobiology of stress (Part 2 of 2 parts)
7. Stress system abnormalities in melancholic and atypical depression: Molecular, pathophysiological, and therapeutic implications
8. Natural history and preventive treatment of recurrent mood disorders
9. Suicide among primary affective disorders
10. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample
11. Minor and major depression and the risk of death in older persons
12. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up
13. Bone mineral density in women with depression
14. Evidence based health policy - Lessons from the Global Burden of Disease study
15. Stressful life events, genetic liability, and onset of an episode of major depression in women
16. The lifetime history of major depression in women. Reliability of diagnosis and heritability
17. Genetic risk factors for major depression in men and women: Similar or different heritabilities and same or partly distinct genes?
18. Genetics of affective disorders
19. Reversed neurovegetative symptoms of depression: A community study
20. Columbia atypical depression. A subgroup of depressives with better responses to MAOI than to tricyclic antidepressants or placebo
21. The validity of major depression with atypical features based on a community study
22. The identification and validation of distinct depressive syndromes in a population-based sample of female twins
23. The concepts of stress and stress system disorders
24. Emotion: Clues from the brain
25. Mechanisms of emotional arousal and lasting declarative memory
26. Glucocorticoids have state-dependent stimulant effects on the mesencephalic dopaminergic transmission
27. Neurocircuitry of stress: Central control of the hypothalamo-pituitary-adrenal axis
28. Editorial: A healthy body in a healthy mind- and vice versa - The damaging power of 'uncontrollable' stress
29. Stress in the wild
30. Psychological stress increased corticotropin-releasing hormone mRNA and content in the central nucleus of the amygdala but not in the hypothalamic paraventricular nucleus in the rat
31. Differential steroid hormone and neural influences on peptide mRNA levels in CRH cells of the paraventricular nucleus: A hybridization histochemical study in the rat
32. Differential regulation of corticotropin-releasing factor mRNA in rat brain regions by glucocorticoids and stress
33. Influence of corticotropin-releasing factor on reproductive functions in the rat
34. Involvement of corticotropin-releasing factor and somatostatin in stress-induced inhibition of growth hormone secretion in the rat
35. Effects of corticotropin releasing hormone on appetitive behaviors
36. Corticotropin-releasing factor is a potent inhibitor of sexual receptivity in the female rat
37. Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by alpha-helical CRF (9-41)
38. Attenuation of stress-induced behavior by antagonism of corticotropin releasing hormone receptors in the central amygdala in the rat
39. Neurobiology of corticotropin releasing factor (CRF) receptors and CRF- binding protein: Implications for the treatment of CNS disorders
40. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development
41. Deletion of crhr2 reveals an anxiolytic role for corticotropin- releasing hormone receptor-2
42. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress
43. Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior
44. Oral administration of a corticotropin-releasing hormone antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses in primates
45. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress
46. CRH-1 receptor antagonism exerts antidepressant- and anxiolytic-like effects in attenuating stress ulcerogenesis
47. Synthesis and biological activity of fluoro-substituted pyrrolo[2,3- d]pyrimidines: The development of potential positron emission tomography imaging agents for the corticotropin-releasing hormone type 1 receptor
48. The development of a potential single photon emission computed tomography (SPECT) imaging agent for the corticotropin-releasing hormone receptor type
49. Role of the locus coeruleus in emotional activation
50. Through the looking glass: Differential noradrenergic modulation of prefrontal cortical function
51. Amygdala modulation of hippocampal-dependent and caudate nucleus- dependent memory processes
52. The prefrontal cortex - An update: Time is of the essence
53. Memory networks in the prefrontal cortex
54. The prefrontal cortex and its relation to behavior
55. Storage and executive processes in the frontal lobes
56. The biology of being frazzled
57. Differential contribution of dorsal and ventral medial prefrontal cortex to the acquisition and extinction of conditioned fear
58. Extinction of emotional learning: Contribution of medial prefrontal cortex
59. A theory of emotion and consciousness, its application to understanding the neural basis of emotion
60. Lateralized effects of medial prefrontal cortex lesions on neuroendocrine and autonomic stress responses in rats
61. Inferior petrosal sinus sampling in healthy human subjects reveals a unilateral corticotropin-releasing-hormone-induced arginine vassopressin release associated with ipsilateral adrenocorticotropin secretion
62. Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness
63. Psychiatric implications of basic and clinical studies with corticotropin-releasing factor
64. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression
65. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications
66. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims
67. Elevated concentrations of CSF corticotropin-releasing-factor-like immunoreactivity in depressed patients
68. Monoamine metabolites, corticotropin releasing factor and somatostatin as CSF markers in depressed patients
69. Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers
70. Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans
71. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications
72. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: Relation to hypercortisolism and corticotropin-releasing hormone
73. Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing's disease and maior depression: Potential clinical implications
74. Abnormal ACTH and cortisol responses to ovine corticotropin releasing factor in patients with primary affective disorder
75. The catecholamine hypothesis of affective disorders: A review of supporting evidence
76. Effects of psychotropic drugs on the uptake of 3H-NE by tissues
77. Brain norepinephrine and dopamine in treatment refractory depression: Evidence in support of the catecholamine hypothesis of depression
78. Transient depressive relapse induced by catecholamine depletion: Potential phenotypic vulnerability marker?
79. Elegated levels of tyrosine hydroxylase in the locus coeruleus in major depression
80. Elevated tyrosine hydroxylase in the locus coeruleus of suicide victims
81. Urinary 3-methoxy-4-hydroxyphenylglycol and major affective disorders. A replication and new findings
82. Tricyclic antidepressants and supine, standing, and exercise plasma norepinephrine levels
83. Cerebrospinal fluid and urinary biogenic amines and metabolites in depression, mania, and healthy controls: A univariate analysis
84. Diagnostic subgroups of affective disorders and their urinary excretion of catecholamine metabolites
85. Effect of ganglion blockade on cerebrospinal fluid norepinephrine
86. Indices of noradrenergic output in depression
87. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls
88. Catecholamines and vasoactive intestinal polypeptide in cerebrospinal fluid in depression
89. Cerebrospinal fluid adrenaline and noradrenaline in depressed patients
90. Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine
91. 3-Methoxy-4-hydroxyphenylglycol in depression
92. MHPG excretion in depressive states. A pilot study
93. Noradrenaline, 5-hydroxytryptamine, and 5-hydroxyindoleacetic acid in hindbrains of suicidal patients
94. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression
95. Sympathetic nervous system activity in major depression: Basal and desipramine-induced alterations in plasma norepinephrine kinetics
96. The peripheral kinetics of norepinephrine in depressive illness
97. High plasma norepinephrine levels in patients with major affective disorder
98. Resting plasma catecholamine concentrations in patients with depression and anxiety
99. The neurobiology of sleep in relation to mental disorder
100. Toward a biochemical classification of depressive disorders, V: Heterogeneity of unipolar depressions
101. Depressive symptom patterns and urinary MHPG excretion
102. Urinary 4-hydroxy-3-methoxyphenylglycol is not a predictor for clinical response to amitriptyline in depressive illness
103. MHPG excretion in depression
104. Biogenic amine metabolites in cerebrospinal fluid of patients with affective disorders
105. Urinary 3-methoxy-4-hydroxyphenylglycol and psychiatric diagnosis
106. CNS monoamine metabolism in bipolar affective disorder. Evaluation using a peripheral decarboxylase inhibitor
107. Determination of monoamine and monoamine metabolites in the human brain: Post mortem studies in a group of suicides and in a control group
108. Role of biogenic amines in certain pathological conditions
109. Differential regulation of corticotropin-releasing hormone and vasopressin gene transcription in the hypothalamus by norepinephrine
110. Corticotropin-releasing hormone mRNA levels in the paraventricular nucleus of patients with Alzheimer's disease and depression
111. Depression in an animal model: Focus on the locus ceruleus function
112. Reserpine exhumed
113. The serotonergic and noradrenergic systems of the hippocampus: Their interactions and the effects of antidepressant treatments
114. Long-term antidepressant treatments result in a tonic activation of forebrain 5HT1a receptors
115. The neurobiology of suicide
116. Long-term treatment with paroxetine decreases the firing of locus ceruleus noradrenergic neurons
117. 5-Hydroxytryptimine2 agonists augment gamma-aminobutyric and excitatory amino acid inputs to locus coeruleus neurons
118. A functional anatomical study of unipolar depression
119. Corticosterone effects on corticotropin-releasing hormone mRNA in the central nucleus of the amygdala and the parvocellular region of the paraventricular nucleus of the hypothalamus
120. The anatomy of melancholia - Focal abnormalities of cerebral blood flow in major depression
121. Changes in regional cerebral blood flow on recovery from depression
122. Subgenual prefrontal cortex abnormalities in mood disorders
123. Lateralized effects of medial prefrontal cortex lesions on neuroendocrine and autonomic stress responses in rats
124. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of US adults
125. C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites
126. Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link?
127. Reflex sympathetic activation induces acute insulin resistance in the human forearm
128. Cardiac hypertrophy in spontaneously hypertensive rats
129. Contributions of neuroendocrine and local autocrine-paracrine mechanisms to the pathophysiology and pharmacology of congestive heart failure
130. The effects of norepinephrine on myocardial biology: Implications for the therapy of heart failure
131. Blood viscosity in human hypertension
132. Role of the sympathetic nervous system in the genesis of ventricular arrhythmia
133. Pathophysiologic and somatic investigations of hypothalamic-pituitary-adrenal axis activation in patients with depression
134. Elevated salivary cortisol in the evening in healthy elderly men and women: Correlation with bone mineral density
135. Effect of dexamethasone on proliferating osteoblasts: Inhibition of prostaglandin E2 synthesis, DNA synthesis, and alterations in actin cytoskeleton
136. Secondary osteoporosis
137. Functional neuroimaging studies of depression: The anatomy of melancholia
138. Regional cerebral blood flow in depression measured by positron emission tomography: The relationship with clinical dimensions
139. The cellular neurobiology of depression
140. A molecular and cellular theory of depression
141. Anaclitic depression in an infant raised in an institution
142. Biology of posttraumatic stress disorder
143. Corticotropin releasing hormone in the pathophysiology of atypical and melancholic depression and in the mechanism of action of antidepressant drugs
144. The corticotropin-releasing hormone stimulation test: A possible aid in the evaluation of patients with adrenal insufficiency
145. Pulsatile administration of human corticotropin-releasing hormone in patients with secondary adrenal insufficiency: Restoration of the normal cortisol secretory pattern
146. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs
147. Psychopathology in patients with endogenous Cushing's syndrome: 'Atypical' or melancholic features
148. Atypical depressive symptoms possibly predict responsiveness to phototherapy in seasonal affective disorder
149. Is seasonal affective disorder a variant of atypical depression? Differential response to light therapy
150. Abnormal pituitary-adrenal responses to corticotropin-releasing hormone in patients with seasonal affective disorder: Clinical and pathophysiological implications
151. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome
152. Low cerebrospinal fluid corticotropin releasing hormone concentrations in eucortisolemic depression
153. The cytokine-HPA axis feed-back circuit
154. Can the chronic fatigue syndrome be defined by distinct clinical features?
155. Extended life-span and stress resistance in the Drosophila mutant methuselah
156. A mutation in the ape-1 gene in Caenorhabditis elegans lengthens life and reduces hermaphrodite fertility
157. Emotion and the amygdala